Latest News on NAGE

Financial News Based On Company


Advertisement
Advertisement

Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging

https://www.quantisnow.com/insight/niagen-bioscience-to-present-at-the-sixth-annual-longevity-summit-6792593
Niagen Bioscience (NAGE) announced that its Senior Director of Global External Research, Dr. Abhijit Kale, will present at the Sixth Annual Longevity Summit at the Buck Institute in Novato, California, on December 9 to 10, 2026. The announcement highlights the company's strong research program, including over 320 research agreements and more than 240 peer-reviewed publications, but contains no new financial results. A proposed multi-year prevention study with Mass General Brigham is also mentioned, though its details are still subject to final agreements.

Niagen Bioscience adds HSA/FSA payment for at-home injection kit

https://www.streetinsider.com/Corporate+News/Niagen+Bioscience+adds+HSAFSA+payment+for+at-home+injection+kit/27331558.html
Niagen Bioscience has partnered with Truemed to enable customers to purchase its Niagen At-Home Injection Kit using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds through its Niagen Plus telehealth platform. This allows qualified customers to save an average of 30% on the $199 kit. The company also highlighted recent open-label clinical trials supporting the product's tolerability and self-reported benefits, noting the importance of confirmation in larger, placebo-controlled studies.

Niagen Bioscience's (NASDAQ:NAGE) Shareholders Have More To Worry About Than Lackluster Earnings

https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/niagen-biosciences-nasdaqnage-shareholders-have-more-to-worr
Niagen Bioscience (NASDAQ:NAGE) recently reported soft earnings, but the author suggests that shareholders may be overlooking more significant issues. The company's high accrual ratio of 0.56 indicates that its reported profit is not well-backed by free cash flow, generating only US$4.6m in FCF against US$10.2m in profit. Additionally, a US$6.8m boost to profit from unusual items further suggests that the statutory profit may not accurately reflect the company's underlying earnings power.

Niagen Bioscience Q3FY26 Results: Revenue falls 10% to $27.2M, net loss $1.2M

https://scanx.trade/stock-market-news/companies/niagen-bioscience-q3fy26-results-revenue-falls-10-27-2m-net-loss-1-2m/55385548
Niagen Bioscience reported a 10% year-over-year decrease in net sales to $27.2 million for Q3FY26, resulting in a net loss of $1.2 million, or $0.01 per diluted share. The decline was attributed to distribution timing issues and competitive pressures, despite growth in direct-to-consumer sales. The company strengthened its cash position to $69.5 million and is advancing its pharmaceutical asset NB4168, with IND-enabling studies targeted for early 2027.

Niagen Bioscience Announces Q3 2026 Earnings and Releases Corporate Presentation via Form 8-K

https://kalkinemedia.com/us/news/announcements/niagen-bioscience-announces-q3-2026-earnings-and-releases-corporate-presentation-via-form-8-k
Niagen Bioscience, Inc. announced its Q3 2026 earnings for the quarter ended September 30, 2026, and released a corporate presentation via a Form 8-K filing on November 4, 2026. The company's press release and corporate presentation were furnished as exhibits to the 8-K, providing financial updates and a business overview, respectively. Niagen Bioscience's Common Stock trades on NASDAQ under the ticker NAGE.
Advertisement

Niagen Bioscience, Inc. (NAGE) Misses Q3 EPS by 3c

https://www.streetinsider.com/Earnings/Niagen+Bioscience%2C+Inc.+%28NAGE%29+Misses+Q3+EPS+by+3c/27290464.html
Niagen Bioscience, Inc. (NAGE) reported a Q3 EPS of ($0.01), missing the analyst estimate of $0.02 by $0.03. The company's revenue for the quarter was $27.2 million, falling short of the consensus estimate of $34.45 million.

Niagen Bioscience earnings missed by $0.03, revenue fell short of estimates

https://uk.investing.com/news/earnings/niagen-bioscience-earnings-missed-by-003-revenue-fell-short-of-estimates-4958463
Niagen Bioscience (NASDAQ: NAGE) reported third-quarter EPS of $-0.010, missing analyst estimates by $0.03, and revenue of $27.2 million, which fell short of the consensus estimate of $34.45 million. The company's stock price has declined significantly over the past 3 and 12 months, and its financial health is rated as "great performance" by InvestingPro.

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results

https://uk.finance.yahoo.com/news/niagen-bioscience-inc-reports-third-210200447.html
Niagen Bioscience, Inc. announced its third quarter 2026 financial results, reporting total net sales of $27.2 million and a net loss of $1.2 million, but achieving positive Adjusted EBITDA of $0.5 million and $2.6 million in operating cash flow for the quarter. The company launched several new products, including Niagen Plus At-Home Injections and Tru Niagen Skincare, and expanded its distribution channels while progressing its pharmaceutical pipeline. Despite a projected investment year in 2026, Niagen Bioscience expects continued growth in 2027 and beyond, particularly in direct website revenues and new product categories.

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results

https://www.businesswire.com/news/home/20261104153325/en/Niagen-Bioscience-Inc.-Reports-Third-Quarter-2026-Financial-Results
Niagen Bioscience, Inc. reported its third-quarter 2026 financial results, with net sales of $27.2 million, including $23.3 million from Tru Niagen, and positive adjusted EBITDA of $0.5 million. The company generated $2.6 million in operating cash flow during the quarter and ended with $69.5 million in cash. Key operational highlights include the launch of Niagen™ At-Home Injection Kit, Tru Niagen® Skincare, and a new brand campaign, alongside expanded distribution and advancements in its pharmaceutical pipeline.

Niagen Bioscience, Inc. Estimates – NASDAQ:NAGE

https://www.tradingview.com/symbols/NASDAQ-NAGE/financials-estimates/
This article provides an overview of Niagen Bioscience, Inc. (NASDAQ: NAGE) financial data and analyst estimates available on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time for both annual and quarterly data.
Advertisement

NAD-boosting supplement fails to improve symptoms in Parkinson’s trial

https://parkinsonsnewstoday.com/news/supplement-fails-improve-parkinsons-symptoms-phase-3-trial/
A Phase 3 clinical trial, NOPARK, found that the NAD-boosting oral supplement nicotinamide riboside (NR) did not improve symptoms in people with early-stage Parkinson's disease compared to a placebo. Although NR successfully increased blood NAD levels, this did not translate into clinical benefits. Researchers concluded that the findings do not support NR as a disease-modifying treatment for Parkinson's.

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

https://finance.yahoo.com/healthcare/articles/niagen-bioscience-report-third-quarter-123200722.html
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its third-quarter financial results, which ended September 30, 2026. The company will release the results via a press release after market close on the same day. Investors can access the live webcast and financial exhibits through the Investor Relations section of Niagen Bioscience's website.

Niagen Bioscience Q3FY26 Results: Earnings call set for Nov 4

https://scanx.trade/stock-market-news/companies/niagen-bioscience-q3fy26-results-earnings-call-set-nov-4/53615074
Niagen Bioscience is scheduled to release its Q3 FY2026 financial results on November 4, 2026, followed by a conference call at 4:30 p.m. ET. The company, a leader in NAD+ science, will discuss its performance, including consumer supplements like Tru Niagen and pharmaceutical developments such as NB4168. Investors can access the press release and webcast via the Investor Relations section of the company's website.

Diluted shares outstanding of Niagen Bioscience, Inc. – HAN:OCD1

https://www.tradingview.com/symbols/HAN-OCD1/financials-income-statement/diluted-shares-outstanding/
This page provides financial data for Niagen Bioscience, Inc. (HAN:OCD1) on TradingView, specifically focusing on the diluted shares outstanding. The article indicates that the market was closed and no trades were made at the time of publication, with data provided by ICE Data Services and FactSet.

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

https://www.businesswire.com/news/home/20261008014757/en/Andrew-Shao-Ph.D.-Senior-Vice-President-of-Global-Regulatory-and-Scientific-Affairs-at-Niagen-Bioscience-Honored-with-the-2026-Annette-Dickinson-Trailblazer-Award-by-Radicle-Science-and-Council-for-Responsible-Nutrition-CRN
Dr. Andrew Shao, Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, has been awarded the 2026 Annette Dickinson Trailblazer Award by Radicle Science and the Council for Responsible Nutrition (CRN). This esteemed award acknowledges Dr. Shao's significant contributions to advancing NAD+ research and promoting scientific rigor and responsible innovation within the dietary supplement industry. The award also honors the legacy of Annette Dickinson, recognizing leaders who embody her dedication to strong science and industry standards.
Advertisement

Restore Hyper Wellness® and Niagen Bioscience Team Up to Help Americans Age Better This October

https://www.prnewswire.com/news-releases/restore-hyper-wellness-and-niagen-bioscience-team-up-to-help-americans-age-better-this-october-302901988.html
Restore Hyper Wellness and Niagen Bioscience have partnered to declare October "Longevity Month," aiming to shift focus from lifespan to healthspan. The initiative highlights five everyday signs that indicate a need for more body support as one ages, emphasizing the importance of recovery and cellular health. They suggest therapies like cryotherapy and IV drips, alongside daily Niagen® plans, to improve energy, resilience, and recovery.

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

https://markets.financialcontent.com/stocks/article/bizwire-2026-10-8-andrew-shao-phd-senior-vice-president-of-global-regulatory-and-scientific-affairs-at-niagen-bioscience-honored-with-the-2026-annette-dickinson-trailblazer-award-by-radicle-science-and-council-for-responsible-nutrition-crn
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, has been honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and the Council for Responsible Nutrition (CRN). This award recognizes Dr. Shao's significant contributions to advancing NAD+ research and promoting scientific excellence within the dietary supplement industry. His career highlights include leadership roles at multinational companies and trade associations, demonstrating a strong commitment to rigorous science and responsible innovation.

NAGE Interactive Stock Chart | Niagen Bioscience, Inc. Stock

https://ca.finance.yahoo.com/chart/NAGE/
This page provides an interactive stock chart for Niagen Bioscience, Inc. (NAGE) on NasdaqCM. As of 11:07:35 a.m. EDT, the stock price was $2.6300, down 3.31%. The chart displays real-time price data and various technical indicators.

Analysts Offer Insights on Consumer Goods Companies: Niagen Bioscience (NAGE) and Target (TGT)

https://www.theglobeandmail.com/investing/markets/stocks/TGT/pressreleases/4978970/analysts-offer-insights-on-consumer-goods-companies-niagen-bioscience-nage-and-target-tgt/
Analysts have issued bullish ratings for Niagen Bioscience (NAGE) and Target (TGT) in the Consumer Goods sector. Canaccord Genuity reiterated a Buy rating for Niagen Bioscience with a $10.00 price target, while Morgan Stanley maintained a Buy rating for Target with a $170.00 price target. Both companies show positive analyst consensus, with Niagen Bioscience having a Strong Buy and Target a Moderate Buy.

A healthy-aging research company’s CEO is set to speak in Los Angeles Oct. 21.

https://www.stocktitan.net/news/NAGE/niagen-bioscience-to-present-at-ld-micro-20th-annual-main-y9lpey8v36hv.html
Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ science and healthy-aging research, announced that its CEO, Robert Fried, will present at the 20th Annual LD Micro Main Event in Los Angeles on October 21, 2026. CFO Ozan Pamir will also be available for one-on-one meetings with institutional investors. The company specializes in NAD+ boosting solutions, with its flagship product Niagen® powering its consumer supplement, Tru Niagen®.
Advertisement

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater

https://finance.yahoo.com/healthcare/articles/niagen-bioscience-puts-25-years-123200934.html
Niagen Bioscience has launched a new campaign, "Don't Get Old. Age Better.®," for its Niagen® brand, featuring 11-time world champion surfer Kelly Slater and over 20 other partners. The campaign emphasizes the company's 25 years of scientific leadership in NAD+ research and its flagship ingredient, Niagen (nicotinamide riboside), which is backed by over 45 peer-reviewed clinical studies. Slater, who continues to compete at 54, highlights the scientific rigor and quality standards of Niagen products for supporting cellular energy and DNA repair, promoting a proactive approach to aging.

Niagen Bioscience, Inc. (NAGE) stock price, news, quote and history

https://au.finance.yahoo.com/quote/NAGE/
Niagen Bioscience, Inc. (NAGE) is a bioscience company specializing in healthy aging products, including dietary supplements and NAD+ precursor nicotinamide riboside. The company's stock closed at $2.69, showing a 1.13% increase, with a market capitalization of $212.849 million. Despite recent declines in its stock price, analysts project a target estimate of $12.08, and the company reported Q2 FY26 revenue of $29.79 million and earnings of $963k.

Niagen Bioscience, Inc. (NAGE) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/NAGE/
Niagen Bioscience, Inc. (NAGE) stock closed at $2.68, down 8.22%, with after-hours trading showing a slight increase. The company, formerly ChromaDex Corporation, focuses on healthy aging products, including its proprietary ingredient Niagen. Key financial data includes a market cap of $213.447M, a P/E ratio of 14.11, and a 1-year target estimate of $12.08, despite significant year-to-date and 1-year stock price declines.

Niagen Bioscience, Inc. (NAGE) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/NAGE/
This article provides detailed financial information for Niagen Bioscience, Inc. (NAGE), including its current stock price, recent performance, key financial metrics, and historical data. It lists real-time trading data, market capitalization, volume, and various valuation measures. The page also includes links to recent news and related stocks.

Niagen Bioscience appoints Dr. Abhijit Kale to lead global research

https://scanx.trade/stock-market-news/companies/niagen-bioscience-appoints-dr-abhijit-kale-to-lead-global-research/45755294
Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will head the Global Niagen Research Program, which currently supports over 175 studies and collaborates with major institutions. Under his leadership, the company aims to expand its research into pharmaceutical-grade applications and explore other NAD+ precursors.
Advertisement

Niagen Bioscience signs agreement for clinical trial planning

https://www.investing.com/news/company-news/niagen-bioscience-signs-agreement-for-clinical-trial-planning-93CH-4925155
Niagen Bioscience Inc. (NASDAQ:NAGE) has signed a Start-Up Agreement with Mass General Brigham to plan a multi-year clinical trial. The trial will evaluate the effects of nicotinamide riboside supplementation in adults aged 50 and older on major clinical outcomes and healthy aging-related measures. This collaboration aims to understand how nutritional interventions impact clinically meaningful outcomes over time, with final design elements still subject to planning and agreements.

Niagen Bioscience to present at Canaccord Genuity’s 46th Annual Growth Conference

https://scanx.trade/stock-market-news/companies/niagen-bioscience-to-present-at-canaccord-genuity-s-46th-annual-growth-conference/46703940
Niagen Bioscience (NASDAQ: NAGE) will present at Canaccord Genuity's 46th Annual Growth Conference in Boston from August 11-13, 2026. CEO Rob Fried and CFO Ozan Pamir will engage with investors, highlighting the company's leadership in NAD+ science and healthy aging. Rob Fried will host a fireside chat on August 11 at 2:00 p.m. ET, and one-on-one meetings will be held with institutional investors.

Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call

https://www.benzinga.com/news/26/09/62073570/transcript-niagen-bioscience-q2-2026-earnings-conference-call
Niagen Bioscience reported Q2 2026 revenue of $29.8 million, with Tru Niagen sales up 6% year-over-year, driven by a 14% increase in e-commerce. The company is expanding beyond supplements into skincare and pharmaceuticals, launching NAD Pharmaceuticals and developing NB4168 for rare genetic diseases, and is also targeting the IV and injection markets with Niagen Plus. Management highlighted the resilience of its core business and expressed confidence in multiple long-term growth engines while maintaining financial discipline and a strong balance sheet.

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater

https://insider.fitt.co/press-release/niagen-bioscience-puts-25-years-of-nad-science-behind-dont-get-old-age-better-a-new-campaign-for-its-niagen-brand-featuring-legendary-surfer-kelly-slater/
Niagen Bioscience has launched a new brand campaign, "Don't Get Old. Age Better.®," for its Niagen® products, featuring legendary surfer Kelly Slater and over 20 other partners. The campaign emphasizes the company's 25 years of scientific leadership in NAD+ research and over 45 peer-reviewed clinical studies on Niagen. It aims to shift perceptions of aging by promoting proactive healthy aging supported by scientific evidence and personal routines of its ambassadors.

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

https://finance.yahoo.com/healthcare/articles/niagen-bioscience-announces-start-agreement-123200260.html
Niagen Bioscience has announced a Start-Up Agreement with Mass General Brigham (MGB) for a clinical trial focused on healthy aging. This proposed multi-year, randomized, placebo-controlled prevention trial aims to evaluate Niagen (nicotinamide riboside) supplementation in adults aged 50 and older, studying its effects on major clinical outcomes and healthy aging-related measures. The collaboration seeks to establish Niagen's long-term benefits and achieve a status comparable to established supplements like multivitamins and fish oil through rigorous, large-scale research.
Advertisement

Niagen Bioscience: Down 68%, But Still Not Quite A Buy (NASDAQ:NAGE)

https://seekingalpha.com/article/4950665-niagen-bioscience-down-68-percent-but-still-not-quite-a-buy
Niagen Bioscience (NAGE) is assigned a "hold" rating due to strong fundamentals and a debt-free balance sheet being offset by limited valuation upside. A DCF analysis estimates the intrinsic value at $2.66 per share, indicating the stock is currently trading above its fair value. While Tru Niagen and e-commerce show growth, weaker ingredient sales and increased spending pressured profitability in Q2.

Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by Analysts

https://www.marketbeat.com/instant-alerts/consensus-niagen-bioscience-inc-nasdaq-nage-given-average-recommendation-of-buy-by-analysts-2026-09-24/
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received an average "Buy" recommendation from analysts, with a 12-month price target of $10.33. Despite recent stock declines, opening at $3.00 near its 12-month low, the company met adjusted earnings per share expectations in its last quarterly report. Institutional investors hold a significant 15.41% stake in the bioscience firm, which specializes in products supporting healthy aging and cellular energy metabolism.

Older mothers’ placentas had less NAD+, a cell-energy molecule. Restoring it improved pregnancy outcomes in aged mice.

https://www.stocktitan.net/news/NAGE/newly-published-preclinical-study-demonstrates-cd38-as-a-driver-of-glxczvy1jakx.html
A new preclinical study published in Nature Communications suggests that the CD38 enzyme drives age-related NAD+ decline in placental tissue, leading to poorer pregnancy outcomes in older mothers. The research indicates that restoring NAD+ levels with nicotinamide riboside (NR) improved placental, fetal, and offspring outcomes in aged mice, and highlights that NR may be more effective than NMN in tissues with high CD38 activity. Niagen Bioscience, while not funding the study, emphasizes its importance in understanding NAD+ decline and the role of different NAD+ precursors.

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

https://uk.finance.yahoo.com/news/niagen-bioscience-engages-veteran-pharmaceutical-123200811.html
Niagen Bioscience has engaged Red Sky Partners and Martin Hendrix, Ph.D., to bolster its drug development program and strategic corporate growth initiatives. These advisors bring extensive experience in biotechnology fundraising, drug development, commercialization, corporate strategy, and M&A, particularly to support the advancement of NB4168, an investigational drug for rare genetic diseases and aging-related disorders. The company aims to leverage their expertise to translate its NAD+ leadership into long-term value and expand its pharmaceutical strategy for unmet medical needs, such as Ataxia Telangiectasia.

Niagen Bioscience engages advisors for drug development strategy By Investing.com

https://uk.investing.com/news/stock-market-news/niagen-bioscience-engages-advisors-for-drug-development-strategy-93CH-4873221
Niagen Bioscience's subsidiary, NAD Pharmaceuticals Corp., has hired Red Sky Partners and Martin Hendrix, Ph.D., as strategic advisors to bolster the development of NB4168 and facilitate corporate growth. The advisors will provide expertise in advancing NB4168, an investigational drug for rare genetic diseases and aging-related disorders, and assist with corporate strategy, business development, and potential M&A initiatives. NB4168 is focused on treating Ataxia Telangiectasia, a condition currently without FDA-approved therapies.
Advertisement

Niagen Bioscience engages advisors for drug development strategy By Investing.com

https://ca.investing.com/news/stock-market-news/niagen-bioscience-engages-advisors-for-drug-development-strategy-93CH-4843479
Niagen Bioscience's subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners and Martin Hendrix, Ph.D., as strategic advisors to advance its investigational drug candidate, NB4168, and support corporate growth. NB4168 targets rare genetic diseases and aging-related disorders, with an initial focus on Ataxia Telangiectasia. The advisors bring extensive experience in biotechnology, business development, and mergers and acquisitions.

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

https://finance.yahoo.com/healthcare/articles/niagen-bioscience-engages-veteran-pharmaceutical-123200811.html
Niagen Bioscience has engaged Red Sky Partners and Martin Hendrix, Ph.D., as strategic advisors to bolster its drug development program and corporate growth. Red Sky Partners will focus on advancing NB4168, an investigational drug for rare genetic diseases, while Dr. Hendrix will advise on broader corporate strategy, business development, and M&A. This move aims to leverage their extensive experience in biopharmaceutical development, strategic transactions, and commercialization to drive the company's next phase of growth.

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

https://finance.yahoo.com/healthcare/articles/niagen-bioscience-present-nasdaq-x-123200971.html
Niagen Bioscience, a company specializing in NAD+ science and healthy aging, announced its participation in the Nasdaq X LD Micro Inaugural SF Summit. CFO Ozan Pamir will present the company's advancements and engage with institutional investors at the event, which features 25 curated public companies. The company is known for its Niagen® product, a patented NAD+ booster, and its focus on advancing healthspan through scientific research.

Niagen Bioscience stock gains GNC, Sam’s Club distribution, Canaccord reiterates buy

https://ca.investing.com/news/stock-market-news/niagen-bioscience-stock-gains-gnc-sams-club-distribution-canaccord-reiterates-buy-93CH-4813794
Niagen Bioscience (NASDAQ:NAGE) has announced expanded retail distribution for its Tru Niagen NAD+ supplement, now available at GNC and Sam’s Club stores. Canaccord Genuity reiterated a Buy rating and a $10.00 price target, citing the expanded distribution and the company's innovation pipeline. The company is also making strides in rare genetic disease treatments with its subsidiary NAD Pharmaceuticals Corp.

Niagen Bioscience stock gains GNC, Sam’s Club distribution, Canaccord reiterates buy

https://www.investing.com/news/analyst-ratings/niagen-bioscience-stock-gains-gnc-sams-club-distribution-canaccord-reiterates-buy-93CH-4873294
Niagen Bioscience (NASDAQ:NAGE) has expanded its retail distribution for its Tru Niagen NAD+ supplement to GNC and Sam’s Club, prompting Canaccord Genuity to reiterate a Buy rating and a $10.00 price target. This expansion is expected to boost sales, alongside the company's innovation pipeline and recent advancements in drug development for rare genetic diseases, such as NB4168 which received Rare Pediatric Disease Designation from the FDA. Despite a recent stock decline, analysis suggests the stock is undervalued with strong gross profit margins.
Advertisement

Niagen Bioscience lists Tru Niagen supplement on Walmart.com

https://m.investing.com/news/swot-analysis/biomarins-swot-analysis-rare-disease-biotech-stock-faces-competitive-headwinds-93CH-4842105?ampMode=1
Niagen Bioscience announced that its Tru Niagen NAD+ supplement is now available on Walmart.com, starting with 300 mg in 30-count and 90-count bottles, with plans for further expansion. CEO Rob Fried stated this move increases accessibility for their "science-backed NAD+ solution." The company highlights Tru Niagen's clinical backing and market position as the leading NAD+ boosting oral supplement in the U.S.

Niagen Bioscience Leads The Way With 2 Promising Penny Stocks

https://www.sahmcapital.com/news/content/niagen-bioscience-leads-the-way-with-2-promising-penny-stocks-2026-08-21
This article highlights several penny stocks with strong financial foundations and growth potential, despite the U.S. market's recent dip. It focuses on Niagen Bioscience (NAGE), Nutriband (NTRB), and Definitive Healthcare (DH), detailing their market caps, operational revenues, recent financial performance, and strategic positioning within their respective industries. The analysis aims to identify promising opportunities for investors interested in smaller, high-growth companies.

Niagen Bioscience Leads The Way With 2 Promising Penny Stocks

https://simplywall.st/stocks/us/healthcare/nasdaq-dh/definitive-healthcare/news/niagen-bioscience-leads-the-way-with-2-promising-penny-stock
This article highlights two penny stocks, Niagen Bioscience (NAGE) and Nutriband (NTRB), that show promise despite the inherent volatility of smaller companies. Niagen Bioscience, with a market cap of US$251.36 million, is expanding its healthy aging products and maintains a debt-free balance sheet. Nutriband, valued at US$43.15 million, is developing transdermal pharmaceutical products and has strengthened its financial position with a new credit line.

Supplement Retail Expansions

https://www.trendhunter.com/amp/trends/niagen-bioscience
Niagen Bioscience has expanded the retail availability of its Tru Niagen product line, including Tru Niagen Beauty, into GNC and Sam's Club stores across 44 states. This move signifies a broader trend of science-backed healthy aging supplements transitioning from niche wellness shops to mainstream retail, making advanced cellular health products more accessible to everyday consumers. The expansion highlights growing consumer interest in NAD+ support for cellular energy, mitochondrial function, and DNA repair, as well as the increasing market for beauty-from-within ingestible supplements.

Niagen Bioscience expands Tru Niagen to GNC, Sam’s Club stores

https://www.investing.com/news/company-news/niagen-bioscience-expands-tru-niagen-to-gnc-sams-club-stores-93CH-4869716
Niagen Bioscience (NASDAQ:NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam’s Club retail locations and online, significantly expanding its retail footprint to nearly 300 stores across 44 states. The expansion includes different product sizes and formulations for each retailer. Tru Niagen is an NAD+ boosting supplement backed by extensive clinical studies.
Advertisement

Niagen Bioscience (Nasdaq:NAGE) - Aktienanalyse

https://simplywall.st/de/stocks/us/household/nasdaq-nage/niagen-bioscience
Niagen Bioscience (Nasdaq:NAGE) is a biotech company focused on healthy aging products, currently trading at US$3.21 with a market capitalization of US$254.5 million. The stock has seen significant volatility, with a 68% drop over the last year, despite recent positive news regarding its drug development program, NB4168, which received Rare Pediatric Disease and Orphan Medicinal Product Designations for Ataxia Telangiectasia. The company has also expanded its product lines, including a telehealth platform and skincare, and recently reported strong Q1 2026 earnings that exceeded analyst expectations.

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club

https://www.eagletribune.com/region/niagen-bioscience-expands-tru-niagen-retail-footprint-with-gnc-and-sam-s-club/article_a6fc6769-9aea-5e50-ae42-e2323c55e851.html
Niagen Bioscience has expanded the retail availability of its Tru Niagen® supplement, now offering it at GNC and Sam's Club stores and online. This move strengthens the company's retail presence and makes the NAD-boosting healthy-aging supplement accessible to a broader consumer base across 44 states. Tru Niagen® is supported by extensive clinical studies and patents, affirming its scientific backing and quality standards.

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club

https://www.nasdaq.com/press-release/niagen-bioscience-expands-tru-niagenr-retail-footprint-gnc-and-sams-club-2026-08-20
Niagen Bioscience announced that its Tru Niagen® healthy aging supplement is now available at nearly 300 GNC and Sam’s Club locations across 44 states and online. This expansion includes Tru Niagen Beauty at GNC and various Tru Niagen 300mg bottle counts at both retailers, significantly strengthening its retail presence. The move reflects growing consumer demand for science-backed healthy aging solutions, leveraging Tru Niagen's clinically proven NAD+ boosting capabilities.

Tieton Capital Management LLC Purchases New Position in Niagen Bioscience, Inc. $NAGE

https://www.marketbeat.com/instant-alerts/filing-tieton-capital-management-llc-purchases-new-position-in-niagen-bioscience-inc-nage-2026-08-20/
Tieton Capital Management LLC has acquired a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE), purchasing over 2 million shares valued at approximately $6.4 million, representing 1.8% of their investment portfolio. Other institutional investors have also recently bought into Niagen Bioscience, with hedge funds and institutional investors collectively owning 15.41% of the company's stock. Analysts generally maintain a "Buy" rating for NAGE, with a consensus price target of $10.33, despite the stock trading significantly below its 52-week high.

Niagen Bioscience CFO Presentation in Chicago Will Be Livestreamed

https://www.stocktitan.net/news/NAGE/niagen-bioscience-to-present-at-the-17th-annual-midwest-ideas-r8bbrqnkz75m.html
Niagen Bioscience (NASDAQ: NAGE) announced that its CFO, Ozan Pamir, will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, in Chicago. The presentation, focusing on the company's investment merits and NAD+ science, will be livestreamed. Niagen Bioscience, a global authority on NAD+, is dedicated to advancing healthspan through its innovative NAD+-boosting solutions, including its consumer supplement Tru Niagen® and pharmaceutical-grade Niagen™ Plus.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement